当前位置: 首页 >> 检索结果
共有 62504 条符合本次的查询结果, 用时 6.4579076 秒

1201. Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell-Derived Cardiac Organoids.

作者: Idan Refael Haim.;Amit Gruber.;Noam Kazma.;Caroline Bashai.;Hava Lichtig Kinsbruner.;Oren Caspi.
来源: Circ Heart Fail. 2025年18卷3期e011690页
The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. A factor contributing to this problem could be the scarcity of in vitro models for HFpEF, which hinders progress in developing new therapeutic strategies. Here, we aimed at developing a novel, comorbidity-inspired, human, in vitro model for HFpEF.

1202. Residual Mitral Regurgitation Interacts With Transmitral Mean Pressure Gradient to Modify the Association With Mortality Following Transcatheter Edge-to-Edge Repair.

作者: Neal M Duggal.;Milo Engoren.;Paul Sorajja.;D Scott Lim.;Jason H Rogers.;Scott M Chadderdon.;Firas E Zahr.;Evelio Rodriguez.;M Andrew Morse.;Enrique Garcia-Sayan.;Nishtha Sodhi.;Marcella A Calfon Press.;Gorav Ailawadi.
来源: Circ Cardiovasc Interv. 2025年18卷2期e014843页
The association, if any, between the transmitral mean pressure gradient (TMPG) after mitral transcatheter edge-to-edge repair and 1-year mortality is controversial in patients undergoing mitral transcatheter edge-to-edge repair with the MitraClip system. We sought to estimate the association between intraoperatively measured residual mitral regurgitation (rMR) and TMPG and 1-year mortality among patients undergoing mitral transcatheter edge-to-edge repair to facilitate decisions on additional devices.

1203. Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy.

作者: Jenny Jia Ling Cao.;William R Miranda.;Barry A Borlaug.;Yogesh N V Reddy.
来源: Circ Heart Fail. 2025年18卷3期e012703页

1204. Cardiorespiratory Fitness Assessment in Stem Cell Transplant Recipients: Getting to the Heart of the Problem.

作者: Justin M Canada.
来源: Circulation. 2025年151卷4期309-311页

1205. SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in Asymptomatic High-Risk Carotid Stenosis.

作者: C David Mazer.;Alan R Moody.;Hwee Teoh.;Adrian Quan.;Randi Elituv.;Thayalasuthan Vivekanandan.;Peiyu Li.;Kevin E Thorpe.;Myriam Lafreniere-Roula.;Raj Verma.;Michael Moroney.;Jack H Casey.;Navneet Singh.;Aditya Bharatha.;Rasha Mahmoud.;Regis Manorajah.;Andrew Jayarajah.;Anish N Kapadia.;Andrew D Dueck.;Mohammed Al-Omran.;Deepak L Bhatt.;Lawrence A Leiter.;Subodh Verma.
来源: Circulation. 2025年151卷4期351-355页

1206. Kidney Decline Predicts Worse Heart Failure Outcomes.

作者: Bridget M Kuehn.
来源: Circulation. 2025年151卷4期348-350页

1207. Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension".

作者: Marius M Hoeper.;Scott Haughie.;Tarek Hassan.;Susanne Vogt.;Sarah Hackley.
来源: Circulation. 2025年151卷4期e32页

1208. Relatively Increased CO2 Delivered to the Brain From the Descending Aorta Leading to an Elevated Respiratory Rate Causing Differential Hypocapnia (RIDDLER or East-West Syndrome): New Pitfalls in Awake Peripheral V-A ECMO.

作者: Alex Rosenberg.;Louit Thakuria.;Christophe Vandenbriele.
来源: Circulation. 2025年151卷4期289-291页

1209. Letter by Yan et al Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension".

作者: Peijing Yan.;Min Zhang.;Yunshan Cao.
来源: Circulation. 2025年151卷4期e31页

1210. Letter by Xing et al Regarding Article, "Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure".

作者: Han Xing.;Chengeng Deng.;Huihui Zhao.
来源: Circ Heart Fail. 2025年18卷3期e012466页

1211. State of the Heart (and Brain) in 2025.

作者: Dhruv S Kazi.
来源: Circulation. 2025年151卷8期515-517页

1212. Unraveling the Role of Myocardial Inflammation in ATTR-CM: A Targetable Mechanism?

作者: Aldostefano Porcari.;Marianna Fontana.;Mattia Riefolo.
来源: Circ Heart Fail. 2025年18卷2期e012652页

1213. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

作者: Seth S Martin.;Aaron W Aday.;Norrina B Allen.;Zaid I Almarzooq.;Cheryl A M Anderson.;Pankaj Arora.;Christy L Avery.;Carissa M Baker-Smith.;Nisha Bansal.;Andrea Z Beaton.;Yvonne Commodore-Mensah.;Maria E Currie.;Mitchell S V Elkind.;Wenjun Fan.;Giuliano Generoso.;Bethany Barone Gibbs.;Debra G Heard.;Swapnil Hiremath.;Michelle C Johansen.;Dhruv S Kazi.;Darae Ko.;Michelle H Leppert.;Jared W Magnani.;Erin D Michos.;Michael E Mussolino.;Nisha I Parikh.;Sarah M Perman.;Mary Rezk-Hanna.;Gregory A Roth.;Nilay S Shah.;Mellanie V Springer.;Marie-Pierre St-Onge.;Evan L Thacker.;Sarah M Urbut.;Harriette G C Van Spall.;Jenifer H Voeks.;Seamus P Whelton.;Nathan D Wong.;Sally S Wong.;Kristine Yaffe.;Latha P Palaniappan.; .
来源: Circulation. 2025年151卷8期e41-e660页
The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs).

1214. Response by Aronson et al to Letter Regarding Article, "Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure".

作者: Doron Aronson.;Yaacov Nitzan.;Daniel Burkhoff.;William T Abraham.
来源: Circ Heart Fail. 2025年18卷3期e012560页

1215. Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications.

作者: Maximilian Leo Müller.;Anna Brand.;Isabel Mattig.;Sebastian Spethmann.;Daniel Messroghli.;Katrin Hahn.;Michele Violano.;Joshua D Mitchell.;Joshua M Hare.;Andrea Frustaci.;Karin Klingel.;Thomas F Lüscher.;Ulf Landmesser.;Bettina Heidecker.
来源: Circ Heart Fail. 2025年18卷2期e012146页
Despite previous histopathologic evidence for its presence, the role of myocardial inflammation in the development and progression of cardiac transthyretin amyloidosis (ATTR-CA) remains insufficiently understood. Thus, this study sought to characterize the prevalence and potential prognostic implications of myocardial inflammation in ATTR-CA.

1216. Differential Associations of Cigar, Pipe, and Smokeless Tobacco Use Versus Combustible Cigarette Use With Subclinical Markers of Inflammation, Thrombosis, and Atherosclerosis: The Cross-Cohort Collaboration-Tobacco Working Group.

作者: Zhiqi Yao.;Erfan Tasdighi.;Zeina A Dardari.;Kunal K Jha.;Ngozi Osuji.;Tanuja Rajan.;Ellen Boakye.;Carlos J Rodriguez.;Kunihiro Matsushita.;Eleanor M Simonsick.;Joao A C Lima.;Rachel Widome.;Debbie L Cohen.;Lawrence J Appel.;Amit Khera.;Michael E Hall.;Suzanne Judd.;Shelley A Cole.;Ramachandran S Vasan.;Emelia J Benjamin.;Aruni Bhatnagar.;Andrew P DeFilippis.;Michael J Blaha.
来源: Circulation. 2025年151卷14期993-1005页
Understanding the associations of tobacco product use with subclinical markers is essential in evaluating health effects to inform regulatory policy. This is particularly relevant for noncigarette products (eg, cigars, pipes, and smokeless tobacco), which have been understudied because of their low prevalence in individual cohorts.

1217. Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure for Clinical Phenotypes.

作者: Yasuyuki Shiraishi.;Nozomi Niimi.;Shun Kohsaka.;Kazumasa Harada.;Takashi Kohno.;Makoto Takei.;Takahiro Jimba.;Hiroki Nakano.;Junya Matsuda.;Akito Shindo.;Daisuke Kitano.;Shigeto Tsukamoto.;Shinji Koba.;Takeshi Yamamoto.;Morimasa Takayama.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e011270页
The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among patients with acute decompensated heart failure, considering their clinical phenotypes.

1218. Vasoactive Medications In Acute Heart Failure: What We Do Not Know Could Indeed Hurt Us.

作者: Deepika Potarazu.;Jason N Katz.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e011825页

1219. Mono and Biallelic Variants in TRIM63 Are Frequently Associated With a Unique Form of Hypertrophic Cardiomyopathy.

作者: Noa Ruhrman Shahar.;Dina Marek-Yagel.;Rotem Greenberg.;Ofer Isakov.;Michal Naftali.;Elena Friedman.;Lily Bazak.;Daniel Monakier.;Alvit Veber.;Nechama Shalva.;Amitai Segev.;Moti Haim.;Lena Sagi-Dain.;Lilach Benyamini.;Adel Shalata.;Sagi Josefsberg Ben Yehoshua.;Lina Basel Salmon.;Sara Hoss.;Shay Ben-Shachar.
来源: Circ Genom Precis Med. 2025年18卷1期e004864页

1220. Putting the Cart Before the Horse: Intravascular Imaging as a Performance Measure.

作者: Adam S Vohra.;Dmitriy N Feldman.
来源: Circ Cardiovasc Interv. 2025年18卷2期e015004页
共有 62504 条符合本次的查询结果, 用时 6.4579076 秒